Table A1.

A non-exhaustive list of patents related to Herceptin® (trastuzumab) as of May 2019.

Subject	Patent number	Date of filing	Applicant	Status
Chimeric Ab	EP0125023	06.04.1984	Genentech	Expired on 06.04.2004
Humanized Ab production	EP0451216 (parent)	28.12.1989	PDL BioPharma	Expired on 28.12.2009
	EP0939127			Expired on 28.12.2009
	EP1477497			Expired on 28.12.2009
	EP1491556			Expired on 28.12.2009
	EP0682040			Revoked
Basic patent	EP0590058 (parent)	15.06.1992	Genentech	Expired on 15.06.2012
	EP1400536			Withdrawn
	EP0940468			Withdrawn
Freeze-dried formulation	EP0845997 (parent)	23.07.1996	Genentech	Withdrawn
	EP1516628			Expired on 23.07.2016. Invalid in Norway and UK.
	EP2275119			Expired on 23.07.2016. Invalid in UK.
Use in treatment of malignant breast cancer, with taxoid	EP1037926 (parent)	10.12.1998	Genentech	Revoked. Invalid in UK.
	EP1947119			Deemed to be withdrawn
	EP2275450			Withdrawn
	EP2277919			Withdrawn
Compositions	EP1075488 (parent)	03.05.1999	Genentech	Expired on 03.05.2019
	EP1308455			Expired on 03.05.2019. Invalid in Belgium, UK, Germany.
	EP1308456			Expired on 03.05.2019
Use in treatment (before/after surgery)	EP1187632	09.05.2000	Genentech	Revoked
Dosages	EP1210115 (parent)	25.08.2000	Genentech	Revoked. Invalid in UK.
	EP2111870			Withdrawn
	EP2110138			Withdrawn
Use in screened cancer patients	EP1282443 (parent)	18.05.2001	Genentech	Revoked
	EP2116262			Withdrawn
Method for purification	EP1648940 (parent)	24.06.2004	Genentech	Granted. Appeal to revocation ongoing.
	EP3095793			Examination in progress
Method for prevention of disulfide bond reduction	EP2188302 (parent)	08.07.2008	Genentech	Granted. Opposition procedure ongoing.
	EP2586788			Granted. Opposition procedure ongoing.
	EP3327026			Examination requested
Subcutaneous formulation	EP2459167 (parent)	28.07.2010	Roche	Active until 28.07.2030
	EP2687202			Examination ongoing

Ab, antibody.